【摘要】 目的探讨雷替曲塞联合奥沙利铂与FOLFOX4方案治疗晚期结直肠癌的疗效及安全性。方法选取我院2012年1月~2015年1月住院治疗的晚期中老年结直肠癌患者116例作为研究对象,随机分为治疗组和对照组。治疗组58例患者应用雷替曲塞联合奥沙利铂方案化疗,对照组58例患者应用FOLFOX4方案,比较两组患者的生存状况、近期疗效、治疗前后生活质量、中医症状评分的变化及毒副反应的发生情况。结果两组间无进展生存期(5.9个月vs.5.8个月)比较,差异无统计学意义(P>0.05)。治疗组有效率略高于对照组(25.9%vs.22.4%),但差异无统计学意义(P>0.05)。治疗后,治疗组乏力、恶心呕吐、腹泻等症状改善明显,躯体、情绪功能及总体生活质量评分均明显优于对照组,且优于本组治疗前(P<0.05)。治疗组中医症状评分较对照组明显降低,与治疗前比较,差异均有统计学意义(P<0.05)。治疗组胃肠道反应发生率明显低于对照组(P<0.05)。结论与FOLFOX4方案相比,雷替曲塞联合奥沙利铂治疗晚期结直肠癌的近期疗效相当,可更有效地改善患者的生活质量,安全性更高。更多还原

【Abstract】 Objective To analyze the efficacy and safety of raltitrexed combined with Oxaliplatin and FOLFOX4 regimenfor treatment of middle-aged and elder patients with colorectal cancer. Methods 116 patients with colorectal cancer were chosen and randomly divided into test group and control group, in which patients were treated by raltitrexed combined with Oxaliplatin and FOLFOX4, respectively. The survival time, short-term curative effect, changes of quality of life before and after treatment, and incidence of toxic reactions were analyzed between the two groups. Results There was no significant difference in the survival time(5.9 month vs. 5.8 month) between the two groups. The total effective rate of control group and test group were 25.9% and 22.4%, respectively, the difference was significant(P>0.05). The symptoms such as fatigue, nausea and vomiting, and diarrhea were significantly improved, the scores of physical function, emotional function, and quality of life after treatment were better in the test group than those of the control group(P<0.05). After treatment, the TCM symptom scores of test group were significantly decreased than those before treatment, while they were significantly increased in the control group than those before treatment and obviously higher than those of the test group(P<0.05). The incidence rates of gastrointestinal reactions in test group were significantly lower than those of the control group after treatment(P<0.05). Conclusion Raltitrexed combined with Oxaliplatin regimen was more effective and safer for colorectal cancer patients than FOLFOX4 regimen.更多还原